Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Hydroxycarbamide in Thalassemia: NCT03825341 Clinical Landscape Report 2026
16 October 2026
NCT03825341 clinical landscape for Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olitigaltin in Idiopathic Pulmonary Fibrosis: NCT03832946 Clinical Landscape Report 2026
16 October 2026
NCT03832946 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ticagrelor in Anemia, Sickle Cell: CTRI/2019/02/017507 Clinical Landscape Report 2026
16 October 2026
CTRI/2019/02/017507 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enlonstobart in Mesothelioma, Malignant: NCT03852823 Clinical Landscape Report 2026
16 October 2026
NCT03852823 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CTX-471 in Locally Advanced Malignant Solid Neoplasm: NCT03881488 Clinical Landscape Report 2026
16 October 2026
NCT03881488 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
MG-1113 in Hemophilia: NCT03855696 Clinical Landscape Report 2026
16 October 2026
NCT03855696 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Trenonacog alfa in Hemophilia B: NCT03855280 Clinical Landscape Report 2026
16 October 2026
NCT03855280 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fidanacogene elaparvovec in Hemophilia B: NCT03861273 Clinical Landscape Report 2026
16 October 2026
NCT03861273 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Setanaxib in Idiopathic Pulmonary Fibrosis: NCT03865927 Clinical Landscape Report 2026
16 October 2026
NCT03865927 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RVT-1601 in Idiopathic Pulmonary Fibrosis: NCT03864328 Clinical Landscape Report 2026
16 October 2026
NCT03864328 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Batoclimab in Myasthenia Gravis: NCT03863080 Clinical Landscape Report 2026
16 October 2026
NCT03863080 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nitric oxide (inhaled) in Pulmonary Disease, Chronic Obstructive: NCT03873298 Clinical Landscape Report 2026
16 October 2026
NCT03873298 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…